Gefurulimab

A4DAB135 | Immune-mediated / inflammatory disorders | Phase-III
C5;ALB
non-canonical / None
Alexion Pharmaceuticals
Phase-III
Whole mAb
ALXN-1720 ALXN1720
—
IMGT PubChem (445594975) PubChem (472425520) PubChem (476000782) PubChem (476262937) PubChem (476269566) PubChem (508534152) Thera-SAbDab YAbS
Avg A4D Score
-0.7061
Score Range
-0.71
Structures
1
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB135_6xy2_H_L 6xy2 100% -0.7061 6.5 9.0 0.0137 -0.8036